Coeptis Therapeutics Holdings Inc

Coeptis Therapeutics operates with a capital structure that includes $250,000 in long-term debt and $13,561,990 in total equity, resulting in a debt-to-equity ratio of 0.02. The company's liquidity position is characterized by a current ratio of 4.16, indicating strong short-term liquidity. However, the company has a negative net cash position after subtracting total debt, which is a key liquidity flag. Profitability metrics show significant challenges, with a return on equity (ROE) of -87.87% and a return on assets (ROA) of -73.77%. These figures are well below the industry median for biotechnology firms, which typically report positive ROE and ROA in the range of 10-20% and 5-10%, respectively. The company reported a net loss of $11,917,020 and an operating loss of $12,884,460 in the latest period. The company's revenue for the period was $1,363,050, with a gross profit of $1,182,420. There is no disclosed segment or geographic breakdown in the available data, so it is not possible to assess revenue concentration or geographic exposure. Looking ahead, the company is expected to continue facing financial challenges, with no clear indication of revenue growth in the next fiscal year. The operating cash flow was -$8,603,040 and free cash flow was -$11,095,980, indicating a significant cash outflow. The outlook for the next fiscal year is not provided in the available data, but the current financial performance suggests continued pressure. The company's risk assessment indicates a medium liquidity risk and a low dilution risk. The low dilution risk is supported by the fact that the number of shares outstanding has not changed between basic and diluted shares, suggesting no imminent dilution from stock options or convertible securities. No recent events such as filings or transcripts are disclosed in the available data.